Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients' response to the drugs infliximab and adalimumab.

(00:32)
 Could you provide a little bit of background information about yourselves?

 

(02:18)
 Would you give the audience a brief overview of the assay?

 

(04:18)
 Which patients should have this testing and when should it be performed? 

 

(07:24)
 What alternative test options are available, and how do these compare?

 

(11:02)
 How are the results used in patient care?